Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach
Journal of Cellular Biochemistry · 2024
DOI: 10.1002/jcb.30533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2024. Verfasst von Kanika Verma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Epidemiology, National Institute of Malaria Research, New Delhi, India. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Folic Acid Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Indian Council of Medical Research, Bundesministerium für Bildung und Forschung (BMBF), Department of Science and Technology (DST).
Abstract (Originalsprache)
Dihydrofolate reductase (DHFR) is a ubiquitous enzyme that regulates the biosynthesis of tetrahydrofolate among various species of Plasmodium parasite. It is a validated target of the antifolate drug pyrimethamine (Pyr) in Plasmodium falciparum ( Pf ), but its clinical efficacy has been hampered due to the emergence of drug resistance. This has made the attempt to screen Food & Drug Administration‐approved drugs against wild‐ and mutant Pf DHFR by employing an in‐silico pipeline to identify potent candidates. The current study has followed a virtual screening approach for identifying potential DHFR inhibitors from DrugBank database, based on a structure similarity search of candidates, followed by absorption, distribution, metabolism, and excretion estimation. The screened drugs were subjected to various parameters like docking, molecular mechanics with generalized born and surface area solvation calculations, and molecular simulations. We have thus identified two potential drug candidates, duloxetine and guanethidine, which can be repurposed to be tested for their efficacy against wild type and drug resistant falciparum malaria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Epidemiology, National Institute of Malaria Research, New Delhi, India.
- Structural Parasitology Lab, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
- Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
- Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
- Department Applied Computer and Bio-Sciences, University of Applied Sciences, Mittweida, Germany.
ORCID-Profile: Praveen K Bharti
Förderung
- Indian Council of Medical Research
- Bundesministerium für Bildung und Forschung (BMBF)
- Department of Science and Technology (DST)
Zitieren
APA
Verma, K., Chaturvedi, R., Lahariya, A. K., Verma, A. K., Schneider, K. A., Anvikar, A. R., & Bharti, P. K. (2024). Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30533
Vancouver
Verma K, Chaturvedi R, Lahariya AK, Verma AK, Schneider KA, Anvikar AR, et al. Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach. Journal of Cellular Biochemistry. 2024. doi:10.1002/jcb.30533
BibTeX
@article{Verma2024,
author = {Verma, Kanika and Chaturvedi, Rini and Lahariya, Ayush K and Verma, Anil K and Schneider, Kristan A and Anvikar, Anup R and Bharti, Praveen K},
title = {Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach},
journal = {Journal of Cellular Biochemistry},
year = {2024},
doi = {10.1002/jcb.30533}
}
EUVIMED